Dr. Richard Wright and Dr. C. Michael Gibson discuss: Transthyretin tetramer destabilization and increased mortality, and the physiologic importance of TTR.
Disclosures: Sponsored by BridgeBio Pharma, Inc
Clinical Trial Results
Search
Dr. Joshua Mitchell and Dr. C. Michael Gibson discuss: Transthyretin tetramer destabilization and increased mortality, and the physiologic importance of TTR.
Disclosures: Sponsored by BridgeBio Pharma, Inc.
Dr. M. Trejeeve Martyn and Dr. C. Michael Gibson discuss: The importance of early screening, diagnosis, and treatment for ATTR-CM
Disclosures: Sponsored by BridgeBio Pharma, Inc.
THIS WEEK IN OBESITY
Participants randomized to the placebo arm in obesity trials often do not lose weight and as a result may drop out […]
THIS WEEK IN OBESITY
Dr. Javed Butler and Dr. C. Michael Gibson discuss the flaws of BMI in obesity trials
#Thisweekinmedicine
Dr. Shinya Goto and I discuss the vexing problem of antiplatelet and anticoagulant therapy in patients with hereditary clotting disorders like hemophilia.
THIS WEEK IN OBESITY
Dr. Javed Butler and I discuss the flaws of BMI in obesity trials
Dr. Gabriel Steg and Dr. C. Michael Gibson discuss the independent contribution of LDL, CRP and Lp(a) to cardiovascular risk including mortality.
While Lp(a) was associated with Major Adverse Cardiovascular Events (MACE), it was not independently associated with all cause or CV […]
#ACC2025 Interventional Wrap Up:
Dr. Merhran and I discuss the HOST-BR trial (optimal DAPT duration for high or low bleeding risk), ECLIPSE trial (orbital […]